1. Home
  2. IMRX vs ACIU Comparison

IMRX vs ACIU Comparison

Compare IMRX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$5.37

Market Cap

340.7M

Sector

Health Care

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.84

Market Cap

288.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMRX
ACIU
Founded
2008
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
340.7M
288.0M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
IMRX
ACIU
Price
$5.37
$2.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$17.20
$10.00
AVG Volume (30 Days)
737.9K
250.4K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
37.75
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.40
$1.60
52 Week High
$10.08
$4.00

Technical Indicators

Market Signals
Indicator
IMRX
ACIU
Relative Strength Index (RSI) 50.04 43.74
Support Level $5.31 $2.80
Resistance Level $5.80 $3.13
Average True Range (ATR) 0.31 0.17
MACD -0.03 -0.02
Stochastic Oscillator 28.99 32.00

Price Performance

Historical Comparison
IMRX
ACIU

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: